Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $4.1500 (-0.95%) ($4.1500 - $4.1500) on Thu. Dec. 9, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.28% (three month average) | RSI | 41 | Latest Price | $4.1500(-0.95%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX declines -4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(53%) ARKG(52%) ARKK(52%) IBUY(50%) ONLN(50%) | Factors Impacting HTBX price | HTBX will decline at least -1.14% in a week (0% probabilities). VXX(-37%) VIXM(-36%) UUP(-15%) TLT(-13%) XLU(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.14% (StdDev 2.28%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-10.97(-364.34%) | Resistance Level | $4.43 | 5 Day Moving Average | $4.07(1.97%) | 10 Day Moving Average | $4.21(-1.43%) | 20 Day Moving Average | $4.43(-6.32%) | To recent high | -34.4% | To recent low | 5.6% | Market Cap | $457m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |